CytomX Therapeutics, Inc.
NASDAQ: CTMX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sean A. McCarthy
- Employees
- 119
- Headquarters
- South San Francisco, United States
- IPO year
- 2015
- Market cap
- $533.9M
- Website
- https://www.cytomx.com
Loading CTMX…
Loading profile data…Frequently asked questions about CTMX
What does CytomX Therapeutics, Inc. (CTMX) do?
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009,...
Where does CTMX trade?
CytomX Therapeutics, Inc. (CTMX) trades on the NASDAQ Global Select.
What sector is CTMX in?
CytomX Therapeutics, Inc. (CTMX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CytomX Therapeutics, Inc.?
Sean A. McCarthy is the chief executive officer of CytomX Therapeutics, Inc. (CTMX).
Where is CytomX Therapeutics, Inc. headquartered?
CytomX Therapeutics, Inc. is headquartered in United States.
Does CTMX pay a dividend?
CytomX Therapeutics, Inc. (CTMX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CTMX go public?
CytomX Therapeutics, Inc. (CTMX) completed its initial public offering in 2015.